The trial investigates a combination therapy of Venetoclax (VEN) and Decitabine (DEC) for patients with acute myeloid leukemia (AML) secondary to myeloproliferative neoplasms (MPNs) who are unfit for intensive chemotherapy. Given the high unmet need in this patient population, successful outcomes could position this combination regimen as a significant treatment option in a niche market. The competitive landscape includes existing therapies for AML, but the specific targeting of sAML with this combination may provide a unique selling proposition. Diligence should focus on the trial's efficacy and safety data, as well as potential regulatory pathways for accelerated approval based on the high unmet need.